JP7032404B2 - ドライアイ疾患の治療のための眼科用組成物 - Google Patents

ドライアイ疾患の治療のための眼科用組成物 Download PDF

Info

Publication number
JP7032404B2
JP7032404B2 JP2019533180A JP2019533180A JP7032404B2 JP 7032404 B2 JP7032404 B2 JP 7032404B2 JP 2019533180 A JP2019533180 A JP 2019533180A JP 2019533180 A JP2019533180 A JP 2019533180A JP 7032404 B2 JP7032404 B2 JP 7032404B2
Authority
JP
Japan
Prior art keywords
composition
cyclosporine
dry eye
ethanol
perfluorobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502197A (ja
JP2020502197A5 (enExample
Inventor
マルクス バイアー，
ヨルク ハイサー，
アリス マイデス，
ゾンニャ クレッサー，
ハートムート フォス，
フランク レッシャー，
バーンハルド グンター，
Original Assignee
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2020502197A publication Critical patent/JP2020502197A/ja
Publication of JP2020502197A5 publication Critical patent/JP2020502197A5/ja
Priority to JP2021215498A priority Critical patent/JP2022050514A/ja
Application granted granted Critical
Publication of JP7032404B2 publication Critical patent/JP7032404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019533180A 2016-12-23 2017-12-20 ドライアイ疾患の治療のための眼科用組成物 Active JP7032404B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021215498A JP2022050514A (ja) 2016-12-23 2021-12-31 ドライアイ疾患の治療のための眼科用組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16206735 2016-12-23
EP16206735.9 2016-12-23
EP17165578.0 2017-04-07
EP17165578 2017-04-07
PCT/EP2017/083770 WO2018115097A1 (en) 2016-12-23 2017-12-20 Ophthalmic composition for treatment of dry eye disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021215498A Division JP2022050514A (ja) 2016-12-23 2021-12-31 ドライアイ疾患の治療のための眼科用組成物

Publications (3)

Publication Number Publication Date
JP2020502197A JP2020502197A (ja) 2020-01-23
JP2020502197A5 JP2020502197A5 (enExample) 2021-02-04
JP7032404B2 true JP7032404B2 (ja) 2022-03-08

Family

ID=61002978

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533180A Active JP7032404B2 (ja) 2016-12-23 2017-12-20 ドライアイ疾患の治療のための眼科用組成物
JP2021215498A Withdrawn JP2022050514A (ja) 2016-12-23 2021-12-31 ドライアイ疾患の治療のための眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021215498A Withdrawn JP2022050514A (ja) 2016-12-23 2021-12-31 ドライアイ疾患の治療のための眼科用組成物

Country Status (14)

Country Link
US (1) US20180360908A1 (enExample)
EP (3) EP3777830B1 (enExample)
JP (2) JP7032404B2 (enExample)
KR (1) KR102288022B1 (enExample)
CN (1) CN110267645A (enExample)
AU (1) AU2017384650B2 (enExample)
BR (1) BR112019012791A2 (enExample)
CA (1) CA3045743C (enExample)
DK (1) DK3399962T3 (enExample)
ES (2) ES2965883T3 (enExample)
MX (1) MX381639B (enExample)
PL (1) PL3399962T3 (enExample)
PT (1) PT3399962T (enExample)
WO (1) WO2018115097A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA2918419C (en) 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
MY206642A (en) * 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) * 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561A1 (en) * 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513586A (ja) 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126602A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) * 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CA2997744C (en) * 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
KR20150095684A (ko) * 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
CN106572941B (zh) * 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513586A (ja) 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Agarwal, P. et al.，Modern approaches to the ocular delivery of cyclosporine A，Drug Discovery Today，2016年06月，Vol.21, No.6，p.977-988，doi:10.1016/j.drudis.2016.04.002
Elyse, L. et al.，Recycling Cyclosporine，Review of Cornea & Contact Lenses，2016年06月15日，p.8-9
Gehlsen, U. et al.，Cyclosporine A using F4H5 as liquid drug carrier is effective in treating experimental dry-eye disease，Investigative Ophthalmology & Visual Science, [online]，2015年06月，Vol.56, No.7，319，ARVO Annual Meeteing Abstract, [retrieved on 2021-01-21], Retrieved from the Internet:<URL: https://iovs.arvojournals.org/article.aspx?articleid=2333034>
Novaliq GmbH Begins Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease，[online]，2016年02月16日，[retrieved on 2021-01-08], Retrieved from the Internet:<URL: https://www.biospace.com/article/releases/novaliq-gmbh-begins-phase-ii-clinical-trial-of-cyclasol-for-the-treatment-of-moderate-to-severe-dry-eye-disease-/>
Sall, K. et al.，Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease，Ophthalmology，2000年，Vol.107, No.4，p.631-639
Scherer, D. et al.，EyeSol: a Novel Topical Ocular Drug Delivery System for Poorly Soluble Drugs，Drug Development & Delivery，2013年，Vol.13, No.1，p.40-44

Also Published As

Publication number Publication date
ES2965883T3 (es) 2024-04-17
US20230043641A1 (en) 2023-02-09
MX381639B (es) 2025-03-13
PT3399962T (pt) 2020-09-03
EP3777830A1 (en) 2021-02-17
PL3399962T3 (pl) 2021-02-08
EP3399962B1 (en) 2020-06-10
BR112019012791A2 (pt) 2019-12-03
AU2017384650A1 (en) 2019-07-04
MX2019007587A (es) 2019-12-16
AU2017384650B2 (en) 2021-02-18
CA3045743C (en) 2023-08-29
EP3777830B1 (en) 2023-11-29
EP3399962A1 (en) 2018-11-14
WO2018115097A9 (en) 2018-08-23
EP3777830C0 (en) 2023-11-29
JP2020502197A (ja) 2020-01-23
US20180360908A1 (en) 2018-12-20
DK3399962T3 (da) 2020-09-07
WO2018115097A1 (en) 2018-06-28
JP2022050514A (ja) 2022-03-30
CN110267645A (zh) 2019-09-20
ES2819005T3 (es) 2021-04-14
EP4374851A3 (en) 2024-08-21
EP4374851A2 (en) 2024-05-29
KR20190100283A (ko) 2019-08-28
KR102288022B1 (ko) 2021-08-10
CA3045743A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP7032404B2 (ja) ドライアイ疾患の治療のための眼科用組成物
US12059449B2 (en) Ophthalmic composition for treatment of dry eye disease
AU2020281641B2 (en) Ophthalmic composition for the treatment of ocular allergy
Garofalo et al. Relieving the symptoms of dry eye disease: update on lubricating eye drops containing hydroxypropyl-guar
Muñoz-Negrete et al. Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial
US12496326B2 (en) Ophthalmic composition for treatment of dry eye disease
HK40113015A (en) Ophthalmic composition for treatment of dry eye disease
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
HK40000392A (en) Ophthalmic composition for treatment of dry eye disease
HK40000392B (en) Ophthalmic composition for treatment of dry eye disease
HK40114301A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504B (en) Ophthalmic composition for treatment of dry eye disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201217

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211231

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211231

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220113

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220224

R150 Certificate of patent or registration of utility model

Ref document number: 7032404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250